Head to Head Review: Rapport Therapeutics (NASDAQ:RAPP) and Compass Therapeutics (NASDAQ:CMPX)

Rapport Therapeutics (NASDAQ:RAPP) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Profitability

This table compares Rapport Therapeutics and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-28.85%	-27.27%
Compass Therapeutics	N/A	-43.61%	-38.05%

Insider and Institutional Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. 13.6% of Rapport Therapeutics shares are owned by insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Rapport Therapeutics and Compass Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48 million	($2.86)	-9.68
Compass Therapeutics	$850,000.00	1,080.54	-$66.49 million	($0.43)	-11.86

Compass Therapeutics has higher revenue and earnings than Rapport Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Rapport Therapeutics and Compass Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1	0	7	1	2.89
Compass Therapeutics	1	0	13	1	2.93

Rapport Therapeutics currently has a consensus price target of $51.40, indicating a potential upside of 85.63%. Compass Therapeutics has a consensus price target of $13.00, indicating a potential upside of 154.90%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Rapport Therapeutics.

Volatility and Risk

Rapport Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Summary

Compass Therapeutics beats Rapport Therapeutics on 8 of the 12 factors compared between the two stocks.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.